Industries > Pharma > Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India

PUBLISHED: 29 March 2018
PAGES: 333
PRODUCT CODE: PHA0297

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0297 Categories: , , Tags: ,

This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 333-page report you will receive 53 tables and 88 figures – all unavailable elsewhere.

The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.

• Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.

• Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.

• Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.

• Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets:
• The US
• Canada
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China

Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

• Discusses parallel import in the US and Europe

Visiongain’s study is intended for anyone requiring commercial analyses for the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. You find data, trends and predictions.

Buy our report today Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018


Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category